O 19: Treatment and Porognosis of Autoimmune Encephalitis

author

Abstract:

AE is a serious medical condition in which the immune system attacks the brain, impairing function. With rapid diagnosis and appropriate treatment, many patients recover most or all functions. However, not all patients experience full recovery; with approximately 6% mortality and other patients who never regain significant brain and/or bodily functions. Autoimmune encephalitis can produce a wide range of neuro-psychiatric symptoms. While the term “autoimmune encephalitis” appears in the medical literature in the 1970’s and 1980’s, the first specific AE antibody was identified in 2005 when Dr. Josep Dalmua described the anti-NMDA-receptor encephalitis type. The disease occurs in men, women and children of all ages. AE is a multi-disciplinary disease. Diagnosis and treatment often requires the combined efforts of multiple specialists including: psychiatrists, neurologists, rheumatologists, and immunologists. As soon as a patient is diagnosed with AE, they should receive one or more of the four (4) first-line treatments. removal of a teratoma (if present) that could be triggering the autoimmune response steroids to reduce immune response and inflammation plasmapheresis to remove harmful antibodies from blood intravenous immunoglobulin (IVIG), which is believed to occupy the binding sites where harmful antibodies attach to brain cells. Second line treatments—immunosuppressant drugs—should be started promptly if first-line treatments fail to improve symptoms. Finally some neurologic article reported that 12% of patients had at least one relapse within two years. 

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

o 19: treatment and porognosis of autoimmune encephalitis

ae is a serious medical condition in which the immune system attacks the brain, impairing function. with rapid diagnosis and appropriate treatment, many patients recover most or all functions. however, not all patients experience full recovery; with approximately 6% mortality and other patients who never regain significant brain and/or bodily functions. autoimmune encephalitis can produce a wid...

full text

O 16: Challenge in Diagnosis and Management of Autoimmune Encephalitis

The first description of an autoimmune encephalitis dates back to 1888, when Hermann Oppenheim described a patient with neurological symptoms but no underlying brain pathology. The field of autoimmune encephalitides associated with antibodies targeting cell-surface antigens is rapidly expanding and new antibodies are discovered frequently. Autoimmune encephalitis is a difficult clinical diagnos...

full text

o 16: challenge in diagnosis and management of autoimmune encephalitis

the first description of an autoimmune encephalitis dates back to 1888, when hermann oppenheim described a patient with neurological symptoms but no underlying brain pathology. the field of autoimmune encephalitides associated with antibodies targeting cell-surface antigens is rapidly expanding and new antibodies are discovered frequently. autoimmune encephalitis is a difficult clinical diagnos...

full text

The Diagnosis and Treatment of Autoimmune Encephalitis.

Autoimmune encephalitis causes subacute deficits of memory and cognition, often followed by suppressed level of consciousness or coma. A careful history and examination may show early clues to particular autoimmune causes, such as neuromyotonia, hyperekplexia, psychosis, dystonia, or the presence of particular tumors. Ancillary testing with MRI and EEG may be helpful for excluding other causes,...

full text

Treatment strategies for autoimmune encephalitis

Autoimmune encephalitis is one of the most rapidly growing research topics in neurology. Along with discoveries of novel antibodies associated with the disease, clinical experience and outcomes with diverse immunotherapeutic agents in the treatment of autoimmune encephalitis are accumulating. Retrospective observations indicate that early aggressive treatment is associated with better functiona...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 2

pages  19- 19

publication date 2017-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023